Apellis Pharmaceuticals(us:APLS)

22.68

+3.70%

Updated on 2025-04-02

Open:21.77
Close:22.68
High:23.77
Low:21.77
Prev Close:21.87
Volume:4.91M
Turnover:111.54M
Turnover Ratio:3.91%
Shares:125.52M
MarketCap:2.85B
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-3032111534077294.79%31124129
2024-03-3133911201771092.37%66101135
2023-12-3131211374800095.14%6479139
2023-09-3035411303445795.50%45123168
2023-06-3034410558681889.80%7098148
2023-03-3129610908262593.89%65104100
2022-12-3128010043976990.67%3596122
2022-09-302709647814987.33%659191
dateorgNametotalratiochangeShareschangeRatio
2024-06-30Wellington Management Group Llp1638869713.47%13306268.84%
2024-06-30Ecor1 Capital, Llc116074259.54%2500002.20%
2024-06-30Avoro Capital Advisors Llc111111119.13%0
2024-06-30Vanguard Group Inc98095528.06%3036863.19%
2024-06-30Blackrock Inc.57952724.76%3006815.47%
2024-06-30State Street Corp41466943.41%123716642.52%
2024-06-30T. Rowe Price Investment Management, Inc.40484123.33%-557309-12.10%
2024-06-30Jennison Associates Llc35914162.95%35090310.83%
2024-06-30Fmr Llc32997902.71%112104851.45%
2024-06-30Jpmorgan Chase & Co31774702.61%96316143.50%

About

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Address:100 5th Avenue

Market Movers